サンバイオの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2017/02/10 | 1,235 | 1,244 | 1,220 | 1,224 | -11 | -0.9% | 99,300 |
2017/02/09 | 1,228 | 1,243 | 1,221 | 1,235 | +4 | +0.3% | 74,800 |
2017/02/08 | 1,233 | 1,242 | 1,222 | 1,231 | -8 | -0.6% | 76,400 |
2017/02/07 | 1,240 | 1,248 | 1,227 | 1,239 | +7 | +0.6% | 60,200 |
2017/02/06 | 1,225 | 1,235 | 1,216 | 1,232 | +16 | +1.3% | 78,000 |
2017/02/03 | 1,222 | 1,232 | 1,207 | 1,216 | +15 | +1.2% | 150,200 |
2017/02/02 | 1,230 | 1,258 | 1,201 | 1,201 | -22 | -1.8% | 222,500 |
2017/02/01 | 1,227 | 1,239 | 1,223 | 1,223 | ±0 | ±0% | 94,800 |
2017/01/31 | 1,264 | 1,264 | 1,222 | 1,223 | -43 | -3.4% | 157,700 |
2017/01/30 | 1,239 | 1,274 | 1,239 | 1,266 | +39 | +3.2% | 190,300 |
2017/01/27 | 1,242 | 1,245 | 1,225 | 1,227 | -10 | -0.8% | 208,100 |
2017/01/26 | 1,259 | 1,261 | 1,219 | 1,237 | -17 | -1.4% | 271,200 |
2017/01/25 | 1,276 | 1,282 | 1,252 | 1,254 | -26 | -2% | 198,600 |
2017/01/24 | 1,284 | 1,288 | 1,280 | 1,280 | -4 | -0.3% | 65,100 |
2017/01/23 | 1,284 | 1,295 | 1,280 | 1,284 | ±0 | ±0% | 80,200 |
2017/01/20 | 1,289 | 1,296 | 1,284 | 1,284 | -2 | -0.2% | 68,000 |
2017/01/19 | 1,294 | 1,305 | 1,286 | 1,286 | -5 | -0.4% | 103,200 |
2017/01/18 | 1,302 | 1,306 | 1,291 | 1,291 | -4 | -0.3% | 86,700 |
2017/01/17 | 1,304 | 1,305 | 1,292 | 1,295 | -10 | -0.8% | 77,300 |
2017/01/16 | 1,305 | 1,321 | 1,295 | 1,305 | ±0 | ±0% | 108,200 |
2017/01/13 | 1,293 | 1,327 | 1,292 | 1,305 | -1 | -0.1% | 106,700 |
2017/01/12 | 1,312 | 1,320 | 1,292 | 1,306 | -19 | -1.4% | 198,300 |
2017/01/11 | 1,312 | 1,330 | 1,311 | 1,325 | +13 | +1% | 135,300 |
2017/01/10 | 1,321 | 1,329 | 1,305 | 1,312 | ±0 | ±0% | 137,700 |
2017/01/06 | 1,338 | 1,345 | 1,309 | 1,312 | -27 | -2% | 205,900 |
2017/01/05 | 1,293 | 1,342 | 1,292 | 1,339 | +53 | +4.1% | 256,400 |
2017/01/04 | 1,303 | 1,319 | 1,286 | 1,286 | -1 | -0.1% | 245,000 |
2016/12/30 | 1,253 | 1,292 | 1,253 | 1,287 | +25 | +2% | 198,000 |
2016/12/29 | 1,259 | 1,270 | 1,248 | 1,262 | +2 | +0.2% | 300,200 |
2016/12/28 | 1,267 | 1,283 | 1,254 | 1,260 | -10 | -0.8% | 222,600 |
2016/12/27 | 1,270 | 1,298 | 1,261 | 1,270 | -1 | -0.1% | 327,600 |
2016/12/26 | 1,232 | 1,272 | 1,230 | 1,271 | +39 | +3.2% | 459,100 |
2016/12/22 | 1,225 | 1,246 | 1,205 | 1,232 | -53 | -4.1% | 643,200 |
2016/12/21 | 1,330 | 1,332 | 1,281 | 1,285 | -55 | -4.1% | 598,800 |
2016/12/20 | 1,329 | 1,342 | 1,327 | 1,340 | +19 | +1.4% | 217,400 |
2016/12/19 | 1,333 | 1,353 | 1,320 | 1,321 | -18 | -1.3% | 346,200 |
2016/12/16 | 1,359 | 1,360 | 1,331 | 1,339 | -17 | -1.3% | 185,500 |
2016/12/15 | 1,388 | 1,389 | 1,345 | 1,356 | -17 | -1.2% | 249,100 |
2016/12/14 | 1,386 | 1,387 | 1,361 | 1,373 | -13 | -0.9% | 128,500 |
2016/12/13 | 1,350 | 1,387 | 1,342 | 1,386 | +29 | +2.1% | 189,500 |
2016/12/12 | 1,385 | 1,390 | 1,345 | 1,357 | -28 | -2% | 271,000 |
2016/12/09 | 1,330 | 1,393 | 1,330 | 1,385 | +31 | +2.3% | 234,400 |
2016/12/08 | 1,384 | 1,387 | 1,325 | 1,354 | -39 | -2.8% | 355,300 |
2016/12/07 | 1,420 | 1,420 | 1,388 | 1,393 | -22 | -1.6% | 166,500 |
2016/12/06 | 1,415 | 1,433 | 1,408 | 1,415 | -5 | -0.4% | 100,200 |
2016/12/05 | 1,430 | 1,437 | 1,409 | 1,420 | +6 | +0.4% | 194,300 |
2016/12/02 | 1,449 | 1,455 | 1,405 | 1,414 | -36 | -2.5% | 216,400 |
2016/12/01 | 1,457 | 1,480 | 1,436 | 1,450 | -15 | -1% | 197,200 |
2016/11/30 | 1,420 | 1,478 | 1,416 | 1,465 | +45 | +3.2% | 295,700 |
2016/11/29 | 1,388 | 1,443 | 1,386 | 1,420 | +22 | +1.6% | 128,700 |
2051~
2100
件表示中 / 2501件
類似銘柄と比較する
現在ご覧いただいている「サンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
サンバイオ | 217,400円 | - | - | 0.00% | - | 100.69倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
科研薬 | 376,400円 | -6.4% | -71.8% | 5.05% | 42.04倍 | 0.94倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の2本柱。後発品も展開 |
ジーエヌアイ | 313,500円 | +21.7% | +999.9% | 0.00% | 13.14倍 | 4.35倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
東和薬品 | 297,800円 | +7.9% | -3.3% | 2.69% | 8.28倍 | 0.85倍 |
|
後発医薬品メーカーで国内2強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
ゼリア新薬 | 204,200円 | +3.1% | -6.5% | 2.35% | 9.47倍 | 1.01倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム